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ABSTRACT
Fahr
’s disease or Fahr
’s syndrome is a rare neurological disorder characterized by abnormal calcified deposits in
the basal ganglia and cerebral cortex. 47 years male who presented to us with progressive ataxia and Parkinsonian
symptoms was found to have extensive bilateral calcifications including bilateral basal ganglia in CT scan of the
brain. The secondary causes of intracranial calcifications were ruled out to make a clinical diagnosis of Fahr
’s
disease. While investigating for chronic low back pain with anemia and renal failure, high ESR and serum protein
electrophoresis showing M band was detected. On further investigation, the bone marrow study confirmed the
diagnosis of multiple myeloma. There are only few case reports of association of Fahr’s disease and multiple
myeloma in literature. The case is being reported here in view of rarity.
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INTRODUCTION
Fahr’s disease    was  first  described  by  a German
neurologist  Karl  Theodar  Fahr  in  1930
1,2 and  is
characterized by abnormal deposition of calcium in
areas of brain that control movements including basal
ganglia,  thalamus,  dentate  nucleus,  cerebral  cortex,
cerebellum,  sub-cortical  white  matter  and
hippocampus. The clinical pattern is variable and the
disease  may  be  sporadic  or  Familial. Genetically  a
locus at 14q has been suggested.
3 A second locus has
been identified on chromosome 8
4 and third one on
chromosome  2,  suggesting  genetic heterogeneity in
this disease.
5 The disease usually appears between the
age of 40-60 years.
1Neuropsychiatric, extrapyramidal
and cerebellar  symptoms,  convulsive seizures,
parkinsonian features; dementia and speech disorders
may  accompany  clinical manifestations. Diagnostic
criteria of  Fahrs  syndrome  has  been  modified  and
derived from Moskowiz et al
6 (1971), Elie et al
7
(1989) and  Manyam
8 (2005) and  can  be  stated as
follows:1. Bilateral  calcification  of  basal  ganglia
visualized  on  neuroimmaging. Other  brain  regions
may also  be  involved. 2. Progressive  neurologic
dysfunction,  which  generally  includes  a  movement
disorder and or neuropsychiatric manifestation. Age
of  onset  is  usually  in  the  fourth  or  fifth  decade,
although  this  dysfunction  may  also  present  in
childhood. 3. Absence of biochemical abnormalities
and somatic features suggestive of mitochondrial or
metabolic disease or other systemic disorder
CASE REPORT
A 47 years Hindu male from middle socioeconomic
status, married and working as a clerk presented to us
in  the  Dept.  of  Medicine, with  progressive
unsteadiness in walking and clumsiness of hands for
around three years. It was associated with memory
loss and emotional outbursts. Initially the symptoms
were slowly progressive and he was able to do his
daily  activities.  But  he  became  more  symptomatic
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around 3 months prior to presenting to us. There was
progressive stiffness of limbs with a tremor of hands
and head nodding. Memory loss was progressing and
limb movements became slower and restricted so that
he was almost confined to a chair. Speech became
more  and  more dysarthric and  social interaction
became more difficult. There was moderate to severe
back  pain  for  around  three  months  at  the  time  of
hospitalization. Around two weeks prior to hospital
admission he was almost bed ridden because of stiff
limbs and back pain. There was no history of head
injury or seizure disorder. He was non- diabetic and
non-hypertensive, non  alcoholic  but  occasional
smoker.  His  father  had  some  movement  disorder
which started at around age of 50 years and he died at
the  age  of  60  years.  No  other  sibling  had  any
movement  disorder  or  similar  symptoms.  He was
treated with vitamins and neuro-protectives from time
to time without any improvement.
On  examination  he  was conscious, oriented,  of
average  body  built  with  pulse  rate  of  70/  min  and
regular and Blood Pressure 130/80 mm of Hg. There
was  pallor  but  no  icterus,  cyanosis,  clubbing  or
lymphadenopathy.  Pedal  edema was  absent and
Jugular  venous  pressure  was  not  raised. On
examination  of  Central  nervous  system,  he  was
conscious and oriented with impaired recent memory
but intact past memory with mini mental score of 22.
Speech  was dysarthric  with presence  of  released
reflexes. There was no cranial nerve involvement or
nystagmus and  motor  examination  revealed  normal
bulk and power with tremor of hands, rigidity in both
upper and lower limbs and all deep tendon jerks in
both upper and lower limbs were brisk and plantar
was bilaterally extensor. There were cerebellar signs
in both upper and lower limbs. There was no sensory
abnormality and skull and spine examination revealed
no  abnormality except  tenderness  over lumbar
vertebrae. Cardiovascular system, chest and abdomen
examination  revealed  no  abnormality. With  a
provisional  diagnosis  of  parkinsonism- dementia
complex and cerebellar dysfunction he was planned
for thorough investigation.
On  routine  pathological  tests  Hb was  3.7G%,  total
leucocyte count was 9,600/cmm with neutrophil 86%,
lymphocytes 12%, and eosinophil 2%. ESR was 120
mm 1
st hour. Comment on peripheral smear showed
microcytic  hypochromic  anemia and  routine
microscopic examination of urine was within normal
limits. Routine biochemical tests showed blood urea
62 mg/dl, serum creatinine 6.5 mg/dl, serum sodium-
137  meq/L, potassium 4.5  meq/L  and  calcium  8.9
meq/L . Fasting and postprandial plasma sugar was
112mg/dl  and  148  mg/dl  respectively. Serum
parathormone (PTH) was 32 ng/L (range 8-50) and
Thyroid function  test  was  within  normal  limits.
Serum protein electrophoresis showed M-Band. (Fig
1) Further  bone  marrow  study showed  plasma cell
infiltration  confirming  diagnosis  of  multiple
myeloma. (Fig 2)
Fig 1:  Serum protein electrophoresis showing M Band
Fig 2: Bone marrow showing plasma cells
Radiological imaging revealed hepatosplenomegally
with reduced cortical-medullary differentiation in the
kidney on  ultrasonography  of the  abdomen and  X-
Ray  of  chest, skull  and  pelvis was  normal. Non
contrast  Computerised  Tomography (NCCT) (Fig
3,4) scan of  brain  showed  multiple  and  diffuse
calcification  in  bilateral  basal  ganglia,  cerebellar
hemispheres,  pons, thalamus, internal  capsule  and
cerebral hemispheres and diagnosis of Fahr’s disease
was considered. Finally the case was diagnosed as a
case of Fahr’s disease with multiple myeloma with
nephropathy  and  anemia.  Neurological  symptoms
were  treated  conservatively.  Oncologists  help  was
sought for multiple myeloma and chemotherapy was776
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started.  Four weeks after starting chemotherapy  he
developed severe sepsis with multi-organ dysfunction
with  septic  shock  and  succumbed. Prognosis  of
Fahr’s disease  is  variable  and  there  is  no  reliable
correlation between age, extent of brain calcification
and  neurological  deficit.  Progressive  neurological
deterioration is invariable and results in disability and
death.
Fig  3:  CT  Scan  of  Brain  showing  calcification  in
bilateral basal ganglia and sub cortical white matter
Fig  4:  CT  scan  of  brain  showing  bilateral  cortical
calcification
DISCUSSION
Fahr’s disease  otherwise  known  as  bilateral
striopallido dentate calcinosis (BSPDC) or idiopathic
basal ganglia calcification is a rare neurodegenerative
disorder of unknown prevalence. This is among the
few  inherited  neurological  conditions  that  lead  to
progressive  dystonia, Parkinsonism and
neuropsychiatric manifestations. As Fahr’s disease is
a progressive neurodegenerative disorder of unknown
etiology,  till  now  there  is  no  definite  cure  and
treatment is symptomatic.
6
The  most  common  presentations  as  per  the
Fahr’sdisease registry are movement disorders, which
account  for  about  55%  of cases.  Among these,
parkinsonism  was  seen  in  57%  cases,  chorea  was
seen in 19% cases, tremor in 8% cases, dystonia in
8%  cases,  athetosis  in  5%  cases  and  orofacial
dyskinesia was seen in 3% case. The other neurologic
manifestations include  cognitive impairment,
cerebellar  signs,  speech  disorders,  pyramidal  signs,
psychiatric  features,  gait  disorders  and  sensory
changes. Various  clinical  conditions  coming  as
differential  diagnosis to Fahr’s disease  are
Parkinson’s disease,  Juvenile  parkinsonism,  other
causes  of  secondary  Parkinsonism  like  post
encephalitic parkinsonism, slow virus infection, drug
induced  parkinsonism,  multi-infarct  dementia  with
parkinsonism, Multisytem degeneration, Huntington
,s
disease and Lewy Body disease
7
Calcification  generally  develops  within  the  vessel
wall  and  in  the  perivascular  space,  ultimately
extending to the neurons. Progressive basal ganglia
mineralization  tends  to  compress  the  vessel  lumen,
thus initiating a cycle of impaired blood flow, neural
tissue  injury  and  mineral  deposition.
1 Deposits  are
composed  of  minerals  like  calcium  phosphate  and
carbonate, glyconate, mucopolysacharide and metals
including  Iron,  Copper,  Magnesium,  Zinc,
Aluminum,  silver  and  cobalt  may  also  be  found.
8,9
Treatment  of Fahr’s disease  is  only
symptomatic.Various  drugs  are  used  to  improve
anxiety,  depression,  obsessive  compulsive  disorder
and to alleviate dystonia. Oxybutinin used for urinary
incontinence  and  antiepileptics  for  seizure.
Haloperidol  and  lithium  carbonate  may  help in
psychotic  symptoms. Levodopa  therapy  for
parkinsonism shows poor response.
10-12
The  etiology of  this  syndrome  does  not  identify  a
specific agent,  but associated with  a  number  of
conditions has been noted. Most common of which
are  endocrine  disorders,  mitochondrial  myopathies,
dermatological abnormalities and infectious diseases.
Among endocrine disorders parathyroid disturbances
are most commonly associated with Fahr’ssyndrome.
1
The  abnormalities  include  idiopathic
hypoparathyroidism,  secondary  hypoparathyroidism,
pseudohypoparathyroidism,  pseudo-pseudo
hypoparathyroidism and hyperparathyroidism. Other
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conditions  associated  with Fahr’s syndrome  are
Kenny  Caffey  Syndrome  Type-1,  Mitochondrial
myopathies like Kearn-Sayre Syndrome and MELAS
(myopathy,  encephalopathy,  lactic acidosis  and
stroke), adult onset neurodegenerative conditions like
neuroferritinopathy  and  polycystic  lipomembranous
osteodysplasia with sclerosing leukoencephalopathy,
dermatological  conditions  like  lipoid  protenosis,
Intrauterine or perinatal infections like toxoplasmosis,
rubella,  CMV or  Herpes virus  infection. Cockayne
syndrome,  Aicardi-Goutieres  Syndrome, Tuberous
sclerosis  complex,  Brucellosis  and  Coats disease  is
also associated with Fahr’s syndrome.
1 There is no
definite treatment available to achieve remission or
stabilization of  Fahrs  disease. Management  is  only
symptomatic with drugs and physiotherapy.
1
But  case  report  showing  association  of  multiple
myeloma  and  Fahr’s  syndrome  is  few  in literature.
Nishiyama et al in 1991 have first reported a 41 year
old  woman  with Fahr’s disease  associated  with
multiple myeloma.
13 The initial symptom of dystonia
and spasticity in the left leg started when she was 30
years old. M protienemia was detected when she was
32  years  and  multiple myeloma  when  she  was  40
years  old.  Periodical  CT  scans  revealed  that  the
intracerebral  calcifications  had  worsened  gradually
through  8  years. Kenji  Isoe  et  al  also reported  the
case of a 66 yr old man with dementia, dysarthria,
rigidity,  pyramidal  signs and  truncal  ataxia  with
calcification  in  basal  ganglia, floor  of  cortices,
subcortical  white  matter  and  cerebellum  associated
with IgG ƛ M proteinemia (MGUS).
14 The patient had
also  calcification  of aorta,  pleura,  pericardium  and
diaphragm. Tentolouris et al have reported three cases
of  familial  calcification  of  aorta  and  calcific  aortic
valve  disease  associated  with  monoclonal ƛ  chain
gammopathy.
15 They  had  indicated  that
immunological  abnormalities  were  associated  with
calcifications. Our case is one among the rare case
reports  of  association  of Fahr’s syndrome  with
multiple  myeloma  or  MGUS  and  we  also  believe
there  may  be  some  immunological basis  associated
with diffuse calcifications of Fahr’s syndrome which
needs further studies.
CONCLUSION
Fahr’s disease  or  Idiopathic  basal  ganglia
calcification is  a  rare  neurological  disorder  with
autosomal dominant transmission. Diagnosis is based
on  some  clinical  criteria,  calcifications  in bilateral
basal  ganglia  and  other  cortical  and  sub  cortical
structures on neuroimmaging and exclusion of other
pathological conditions causing bilateral intracranial
calcifications. Progressive neurological deterioration
generally results in disability and death. Treatment is
only  symptomatic  and  prognosis  is  variable. This
disorder  is  associated  with  a variety  of  other
metabolic,  endocrine  and  genetic disorders,  but no
specific  etiology  has  been  identified  yet.  From  the
various  case  reports  of  association  of  multiple
myeloma with Fahr’s disease or diffuse calcification
of aorta and aortic valves including our case report it
appears that there is some immunological basis to the
development  and  progression  of  calcification  in
Fahr’s disease. Further study is required to find out
exact molecular mechanism involved which may also
lead to exploration of therapeutic options.
Conflict of interest: None
REFERENCES
1. Saleem  S,  Aslam  HM,  Anwar  M, Anwar  S,
Saleem M, Saleem A, Rehmani M A K : Fahrs
syndrome: Literature review of current evidences.
Orphanet Journal of Rare Diseases. 2013;8:156
2. Fahr  T. Idiopathische  Verkalkung  der
hirngefasse. Zentrabl Allg Pathol 1930; 50:129-
33
3. Geschwind  DH,  Loginvo  M,  Stern  JM.
Identification of a locus on chromosome 14q  for
idiopathic  basal  ganglia  calcification  (Fahr’s
disease). Am. J. Hum.Genet. 1999;65(3): 764-72
4. Oliveira  JR,  Spiteri  E,  Sorbido  MJ. Genetic
heterogeneity in Familial idiopathic calcification
(Fahr’sdisease). Neurology. 2004;63(11):2165-7
5. Dai X, Gao Y, Xu Z. Identification of a novel
genetic locus on chromosome 8p21.1q11.23 for
idiopathic basal ganglia calcification. Am J.Med
Genet.B  Neuropsychiatr  Genet.
2010;153B(7):1305-10
6. Moskowitz  MA,  Winickoff  RN,  Heinz  ER.
Familial  calcification  of  the  basal  ganglions:  a
metabolic  and  genetic  study.  N  Engl  J  Med
1971;285(2):72-77
7. Ellie  E, JulienJ,  Ferrer  X.  Familial  idiopathic
striopallidodentate  calcifications.  Neurology
1989,39(3):381-85778
Tripathy et al., Int J Med Res Health Sci. 2014;3(3):774-778
8. Manyam  BV.  What  is  and  what  is  not  “Fahr’s
disease.” Parkinsonism  Relat  Disord.
2005,11(2):73-80
9. Athulya  GA, Sydney  D,  Suza,  Jayakumar  J,
Sivananda P. Fahrs syndrome-An interesting case
presentation. Clin Diagn Res. 2013;7(3):532-33
10. Manyam B V, Waters AS, Narla KR. Billateral
striopallido  dentate  calcinosis: clinical
characteristics of patients seen in aregistry. Mov
Disord.  2001;16(2):258-64
11. Bouras C,  Giannakopoulos P,  Good  P,  Hsu  A,
Hof P, Perl D. A laser microprobe mass analysis
of  trace  elements  in  brain mineralization  and
capillaries  in Fahr’s disease.  Acta  Neuropathol.
1996;92(4):351-57
12. Beall  SS,  Patten  BM,  Mallette  L,  Jankovic  J.
Abnormal    systemic  metabolism  of  iron,
porphyrin and calcium in Fahr’ssyndrome. Ann
Neurol .1989;26(4):569-75
13. Nishiyama  K, Honda  E, Mizuno  T. A  case  of
idiopathic, symmetrical,  non arteriosclerotic
intracerebral calcification (Fahr’sdisease)
associated  with  M-proteinemia  followed  by
multiple  myeloma. Rinsho  Shinkeigaku
1991;31:781-84
14. Kenji I,Katsuya U,Mikio S, Kenji N .Intracranial
calcification with IgG ƛ M-proteinemia: a case
report. J  Neurol  Neurosurg  Psychiatry
1998;64:561-63
15. Tentolouris  C, Kontozoglou  T, Toutouzas  P.
Familial  calcification  f  aorta  and  calcific  aortic
valve  disease  associated  with  immunologic
abnormalities. Am Heart J.1993;126:904-09